The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Class: Antithyroid agent
- Tablets 50 mg
Inhibits synthesis of thyroid hormones.
Readily absorbed from the GI tract.
Indications and Usage
For treatment of patients with Graves disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment regimen; to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.
Management of alcoholic liver disease.
Hypersensitivity to propylthiouracil or any of the product's components.
Dosage and AdministrationAdults
PO 300 mg/day in 3 equal doses every 8 h initially. In patients with severe hyperthyroidism or very large goiters, initial dosage may be increased to 400 mg/day, occasionally up to 600 to 900 mg/day. The maintenance dosage is 100 to 150 mg/day in divided doses every 8 h.Children 6 y of age and older
PO Propylthiouracil is generally not recommended for use in children, except in rare instances in which other alternative therapies are not appropriate options. The initial dosage is 50 mg/day in divided doses every 8 h. Carefully titrate upward based on clinical response and evaluation of TSH and free T4 levels.
Give with meals to minimize GI irritation.
Store at 59° to 86°F.
Drug InteractionsAnticoagulants, oral (eg, warfarin)
The activity of anticoagulants may be potentiated by anti–vitamin K activity attributed to propylthiouracil. Monitor PT/INR and adjust the warfarin dose as needed.Beta-blockers (eg, propranolol)
Increased effects of beta-blockers. A dose reduction of beta-blockers may be needed when a hyperthyroid patient becomes euthyroid.Corticosteroids (eg, prednisolone)
Propylthiouracil may decrease pharmacologic effects and plasma concentrations of corticosteroids. Larger corticosteroids doses may be needed during coadministration of propylthiouracil.Digitalis glycosides (eg, digoxin)
Increased digitalis levels, resulting in toxicity. A dose reduction of digitalis glycoside may be needed when a hyperthyroid patient becomes euthyroid.Theophylline
Altered theophylline Cl in hyperthyroid or hypothyroid patients. A dose reduction of theophylline may be needed when a hyperthyroid patient becomes euthyroid.
Drowsiness, headache, neuritis, paresthesia, vertigo.
Abnormal hair loss, erythema nodosum, exfoliative dermatitis, lupus-like syndrome (splenomegaly, vasculitis), pruritus, rash, skin pigmentation, skin rash, skin ulcers, urticaria.
Epigastric distress, loss of taste, nausea, taste perversion, vomiting.
Hepatitis; jaundice; liver failure; liver injury resulting in hepatitis; a need for transplantation.
Aplastic anemia, hypoprothrombinemia and bleeding, myelopoiesis (eg, agranulocytosis, granulopenia, thrombocytopenia).
Alveolar hemorrhage, interstitial pneumonitis, pulmonary infiltrates.
Antineutrophil cytoplasmic antibody (ANCA)–positive vasculitis syndrome, including rapidly progressive glomerulonephritis sometimes leading to acute renal failure; drug fever; edema; leukocytoclastic vasculitis; lymphadenopathy; periarteritis; sialadenopathy.
Severe liver injury and acute liver failure, sometimes fatal or requiring liver transplantation, have been reported. Reserve for patients who are intolerant to methimazole and are not candidates for radioactive iodine or surgery.Pregnancy
Because of the risks of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid agent is indicated during or just prior to the first trimester.
Periodically monitor thyroid function tests and prothrombin time during therapy. Measure alkaline phosphatase, ALT, AST, and bilirubin if symptoms of hepatic dysfunction occur. Measure CBC with differential if symptoms of infection develop.
Category D . Cases of liver injury, including liver failure and death, have been reported in pregnant women using propylthiouracil. Other agents (eg, methimazole) may be preferred following the first trimester of pregnancy.
Severe liver injury, including hepatic failure requiring liver transplantation or resulting in death, has been reported in children. Propylthiouracil is not recommended for use in children except in rare instances in which methimazole is not well-tolerated and surgery or radioactive iodine therapy is not appropriate.
Agranulocytosis, a potentially life-threatening adverse reaction, may occur. Leukopenia, thrombocytopenia, and aplastic anemia may also occur.
May cause hypoprothrombinemia and bleeding.
Agranulocytosis; arthralgia; CNS depression or stimulation; edema; epigastric distress; exfoliative dermatitis; fever; headache; hepatitis; nausea; neuropathy; pancytopenia; pruritus; vomiting.
- Instruct patient to take resting pulse daily and encourage patient to keep recorded chart.
- Advise patient to monitor weight at least 2 to 3 times/wk or per health care provider instruction, obtaining weight at same time, using same scale. Encourage patient to keep recorded chart.
- Emphasize importance of following dietary restrictions regarding shellfish, iodized salt, and other foods high in iodine.
- Explain that desired response may take several months if the thyroid is greatly enlarged.
- Advise patient to carry medical identification (eg, card, bracelet) at all times describing medications.
- Instruct patient to notify dentist or health care provider of drug regimen before surgical or dental procedures.
- Emphasize importance of follow-up visits to monitor effectiveness of drug therapy.
- Caution patient not to stop taking medication abruptly to avoid thyroid crisis.
- Instruct patient to report the following symptoms to health care provider: sore throat, fever, rash, mouth sores; cold intolerance, mental depression; tachycardia, irritability; persistent nausea, steatorrhea, or vomiting; drowsiness; yellowing of skin or whites of eyes; unusual bleeding or bruising.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other activities requiring mental alertness.
Copyright © 2009 Wolters Kluwer Health.